States, J C <br/><br/>
Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.  [electronic resource] 

 -  Cancer letters  Nov 1996 
 - 233-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0304-3835 
<br/><br/><label>Standard No.: </label>10.1016/s0304-3835(96)04428-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Cisplatin--pharmacology<br/>DNA-Binding Proteins--genetics<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Gene Amplification<br/>Humans<br/>Mutation--genetics<br/>Neoplasm Proteins--genetics<br/>Ovarian Neoplasms--genetics<br/>Polymorphism, Single-Stranded Conformational<br/>RNA, Messenger--genetics<br/>Tumor Suppressor Protein p53--metabolism<br/>Xeroderma Pigmentosum Group A Protein